tetano
Editor, Senior Moderator
BMJ Open
. 2023 Mar 27;13(3):e067002.
doi: 10.1136/bmjopen-2022-067002.
Immune and metabolic markers for identifying and investigating severe Coronavirus disease and Sepsis in children and young people (pSeP/COVID ChYP study): protocol for a prospective cohort study
Sivakumar Oruganti[SUP] 1 [/SUP], Patrícia R S Rodrigues[SUP] 2 [/SUP], Daniel White[SUP] 2 [/SUP], William John Watkins[SUP] 3 [/SUP], Selyf Shapey[SUP] 4 [/SUP], Anna Barrow[SUP] 4 [/SUP], Rim Al Samsam[SUP] 4 [/SUP], Sara Ali[SUP] 4 [/SUP], Malcolm Gajraj[SUP] 4 [/SUP], Richard Skone[SUP] 5 [/SUP], Michelle Jardine[SUP] 4 [/SUP], Jennifer Evans[SUP] 4 [/SUP], Siske Struik[SUP] 4 [/SUP], Jong Eun Song[SUP] 4 [/SUP], Lloyd Abood[SUP] 6 [/SUP], Barbara Paquete[SUP] 4 [/SUP], Sian Foulkes[SUP] 4 [/SUP], Benjamin Saunders[SUP] 7 [/SUP], Angela Strang[SUP] 2 [/SUP], Sarah Joanne Kotecha[SUP] 8 [/SUP], Bethan Phillips[SUP] 9 [/SUP], Awen Evans[SUP] 9 [/SUP], Iona Buchanan[SUP] 9 [/SUP], Susan Bowes[SUP] 9 [/SUP], Begum Ali[SUP] 9 [/SUP], Maya Gore[SUP] 9 [/SUP], Rhian Thomas-Turner[SUP] 9 [/SUP], Robert Andrews[SUP] 2 [/SUP], Summia Zaher[SUP] 10 [/SUP], Simran Sharma[SUP] 11 12 [/SUP], Mallinath Chakraborty[SUP] 13 [/SUP], Edward Parkinson[SUP] 2 [/SUP], Federico Liberatore[SUP] 2 [/SUP], Thomas Woolley[SUP] 2 [/SUP], Sarah Edkins[SUP] 2 [/SUP], Luke C Davies[SUP] 2 [/SUP], Linda Moet[SUP] 2 [/SUP], James E McLaren[SUP] 2 [/SUP], Gareth L Watson[SUP] 2 [/SUP], Valerie O'Donnell[SUP] 14 [/SUP], Kerry Hood[SUP] 14 [/SUP], Peter Ghazal[SUP] 15 [/SUP]
Affiliations
Abstract
Introduction: Early recognition and appropriate management of paediatric sepsis are known to improve outcomes. A previous system's biology investigation of the systemic immune response in neonates to sepsis identified immune and metabolic markers that showed high accuracy for detecting bacterial infection. Further gene expression markers have also been reported previously in the paediatric age group for discriminating sepsis from control cases. More recently, specific gene signatures were identified to discriminate between COVID-19 and its associated inflammatory sequelae. Through the current prospective cohort study, we aim to evaluate immune and metabolic blood markers which discriminate between sepses (including COVID-19) from other acute illnesses in critically unwell children and young persons, up to 18 years of age.
Methods and analysis: We describe a prospective cohort study for comparing the immune and metabolic whole-blood markers in patients with sepsis, COVID-19 and other illnesses. Clinical phenotyping and blood culture test results will provide a reference standard to evaluate the performance of blood markers from the research sample analysis. Serial sampling of whole blood (50 μL each) will be collected from children admitted to intensive care and with an acute illness to follow time dependent changes in biomarkers. An integrated lipidomics and RNASeq transcriptomics analyses will be conducted to evaluate immune-metabolic networks that discriminate sepsis and COVID-19 from other acute illnesses. This study received approval for deferred consent.
Ethics and dissemination: The study has received research ethics committee approval from the Yorkshire and Humber Leeds West Research Ethics Committee 2 (reference 20/YH/0214; IRAS reference 250612). Submission of study results for publication will involve making available all anonymised primary and processed data on public repository sites.
Trial registration number: NCT04904523.
. 2023 Mar 27;13(3):e067002.
doi: 10.1136/bmjopen-2022-067002.
Immune and metabolic markers for identifying and investigating severe Coronavirus disease and Sepsis in children and young people (pSeP/COVID ChYP study): protocol for a prospective cohort study
Sivakumar Oruganti[SUP] 1 [/SUP], Patrícia R S Rodrigues[SUP] 2 [/SUP], Daniel White[SUP] 2 [/SUP], William John Watkins[SUP] 3 [/SUP], Selyf Shapey[SUP] 4 [/SUP], Anna Barrow[SUP] 4 [/SUP], Rim Al Samsam[SUP] 4 [/SUP], Sara Ali[SUP] 4 [/SUP], Malcolm Gajraj[SUP] 4 [/SUP], Richard Skone[SUP] 5 [/SUP], Michelle Jardine[SUP] 4 [/SUP], Jennifer Evans[SUP] 4 [/SUP], Siske Struik[SUP] 4 [/SUP], Jong Eun Song[SUP] 4 [/SUP], Lloyd Abood[SUP] 6 [/SUP], Barbara Paquete[SUP] 4 [/SUP], Sian Foulkes[SUP] 4 [/SUP], Benjamin Saunders[SUP] 7 [/SUP], Angela Strang[SUP] 2 [/SUP], Sarah Joanne Kotecha[SUP] 8 [/SUP], Bethan Phillips[SUP] 9 [/SUP], Awen Evans[SUP] 9 [/SUP], Iona Buchanan[SUP] 9 [/SUP], Susan Bowes[SUP] 9 [/SUP], Begum Ali[SUP] 9 [/SUP], Maya Gore[SUP] 9 [/SUP], Rhian Thomas-Turner[SUP] 9 [/SUP], Robert Andrews[SUP] 2 [/SUP], Summia Zaher[SUP] 10 [/SUP], Simran Sharma[SUP] 11 12 [/SUP], Mallinath Chakraborty[SUP] 13 [/SUP], Edward Parkinson[SUP] 2 [/SUP], Federico Liberatore[SUP] 2 [/SUP], Thomas Woolley[SUP] 2 [/SUP], Sarah Edkins[SUP] 2 [/SUP], Luke C Davies[SUP] 2 [/SUP], Linda Moet[SUP] 2 [/SUP], James E McLaren[SUP] 2 [/SUP], Gareth L Watson[SUP] 2 [/SUP], Valerie O'Donnell[SUP] 14 [/SUP], Kerry Hood[SUP] 14 [/SUP], Peter Ghazal[SUP] 15 [/SUP]
Affiliations
- PMID: 36972964
- DOI: 10.1136/bmjopen-2022-067002
Abstract
Introduction: Early recognition and appropriate management of paediatric sepsis are known to improve outcomes. A previous system's biology investigation of the systemic immune response in neonates to sepsis identified immune and metabolic markers that showed high accuracy for detecting bacterial infection. Further gene expression markers have also been reported previously in the paediatric age group for discriminating sepsis from control cases. More recently, specific gene signatures were identified to discriminate between COVID-19 and its associated inflammatory sequelae. Through the current prospective cohort study, we aim to evaluate immune and metabolic blood markers which discriminate between sepses (including COVID-19) from other acute illnesses in critically unwell children and young persons, up to 18 years of age.
Methods and analysis: We describe a prospective cohort study for comparing the immune and metabolic whole-blood markers in patients with sepsis, COVID-19 and other illnesses. Clinical phenotyping and blood culture test results will provide a reference standard to evaluate the performance of blood markers from the research sample analysis. Serial sampling of whole blood (50 μL each) will be collected from children admitted to intensive care and with an acute illness to follow time dependent changes in biomarkers. An integrated lipidomics and RNASeq transcriptomics analyses will be conducted to evaluate immune-metabolic networks that discriminate sepsis and COVID-19 from other acute illnesses. This study received approval for deferred consent.
Ethics and dissemination: The study has received research ethics committee approval from the Yorkshire and Humber Leeds West Research Ethics Committee 2 (reference 20/YH/0214; IRAS reference 250612). Submission of study results for publication will involve making available all anonymised primary and processed data on public repository sites.
Trial registration number: NCT04904523.